Andrew Tiu is an Oncology physician. OpenAlex indexes 56 publications with 328 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2300 Fall Hill Ave Ste 317
Fredericksburg, VA 224013343
Telephone
540-741-4257Provider last certified this registry record 16 Jun 2024.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Eisai Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
73.4%Corticosteroid73.4%Dexamethasone sodium phosphate100%Part B, office-administered≥13 patientsNervous system
16.1%Opioid Agonist16.1%Oxycodone Hcl63%Morphine Sulfate Er38%Part D<11 patientsBlood & clotting
10.6%Factor Xa inhibitor10.6%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic Impact of Pre-Transplant Measurable Residual Disease in Acute Myeloid Leukemia: A Bayesian Meta-Analysis of Contemporary Allogeneic Hematopoietic Cell Transplantation Cohorts
Biology of Blood and Marrow Transplantation
2026 - Risk of myeloproliferative neoplasms among <scp>U.S.</scp> Veterans from Korean, Vietnam, and Persian Gulf War eras
American Journal of Hematology
2024 - Patient reported outcomes among U.S. Veterans living with myeloproliferative neoplasms.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”